Gentle hand applying skin-lightening cream with glowing effect

Hydroquinone and Skin Irritation: The TRPA1 Connection

Soraya Malik monogram
Soraya Malik in Health & Wellness October 2026 • 4 min read.

"New research sheds light on how hydroquinone, a popular skin-lightening agent, triggers irritation—and how it can be prevented."


Hyperpigmentation disorders can affect people's well-being, leading many to seek treatment. Hydroquinone (HQ) is a common and effective ingredient in skin-lightening products, addressing conditions like post-inflammatory hyperpigmentation, melasma, and solar lentigines. However, the benefits of HQ often come with a significant drawback: skin irritation.

While HQ is valued for its ability to reduce skin darkening, it frequently causes burning, itching, and redness, leading to discomfort and potentially reducing adherence to treatment. Current strategies to manage this irritation often involve topical steroids, which can introduce their own set of side effects with long-term use. Understanding the underlying mechanisms of HQ-induced irritation is crucial for developing more tolerable treatments.

Recent research has uncovered a key player in HQ-induced skin irritation: the TRPA1 receptor. This article will delve into the specifics of this discovery, exploring how HQ activates TRPA1 and how this activation leads to irritation and pain. We'll also discuss how this knowledge can pave the way for new, more comfortable skin-lightening options.

AI Search Multiple angles on this topic

Investigating Hydroquinone-Related Irritation

Hydroquinone is described as a widely used skin-lightening treatment whose side effects can include bothersome irritation. The article on hydroquinone and TRPA1 explores whether activation of this receptor helps explain that irritation and could point toward gentler treatments. A separate study notes that the mechanisms behind sensory irritation from chemicals on the skin surface remain unknown, while identifying TRPA1 and TRPV1 as relevant to sensing painful and temperature stimuli.

TRPA1: The Culprit Behind Hydroquinone Irritation?

Gentle hand applying skin-lightening cream with glowing effect

The study published in Scientific Reports, demonstrates that hydroquinone (HQ) is an activator of the peripheral irritant receptor transient receptor potential (TRP) cation channel member A1 (TRPA1). The team of researchers investigated the effects of HQ on TRPA1, TRPV1, TRPV4, and TRPM8 channels. Results showed that TRPA1 got activated. However, HQ failed to activate TRPV1, TRPV4, or TRPM8.

TRPA1, primarily found in sensory neurons, is known to respond to various irritating stimuli. When activated, it can trigger pain, itching, and inflammation. The researchers found that HQ directly activates TRPA1, leading to the release of neuropeptides that contribute to neurogenic inflammation.

  • Specific Activation: HQ specifically targets TRPA1, without affecting other related receptors like TRPV1, TRPV4, and TRPM8.
  • Redox Sensitivity: TRPA1 activation depends on redox-sensitive cysteine and lysine residues, meaning that HQ’s chemical interactions are crucial for its effect.
  • Sensory Neuron Response: HQ causes calcium influx in sensory neurons, indicating activation of these cells, a response reduced in TRPA1-deficient mice.
  • Pain and Hyperalgesia: In mice, HQ injection induces acute pain and hyperalgesia, both significantly reduced by TRPA1 inhibitors.
AI Search Multiple angles on this topic

TRPA1 in Irritation Research

A review reports that Tai et al. (2017) identified TRPA1 activation as the mechanism responsible for hydroquinone-induced skin irritation. Another source notes that skin-whitening agents such as hydroquinone and arbutin can cause irritation and pain. In a separate line of research, a study of 2-chlorobenzalmalononitrile (CS) tear gas found acute and persistent skin injuries and reported that TRPA1 antagonists ameliorated those injuries. A study focused on sensory irritation from chemicals on the skin surface says its mechanisms remain unknown and investigates the roles of TRPA1 and TRPV1.

Limits of the TRPA1 Evidence

In a cell-based test, hydroquinone activated TRPA1 but not the other tested TRP channels or empty-vector-transfected cells. The Nature source also says that further detailed analysis of TRPA1 expression in skin and skin cells is needed; its data suggest skin cells produce minimal TRPA1 and that most skin TRPA1 is on sensory nerve endings. That source additionally reports that zinc, which is also used to treat skin hyperpigmentation, robustly activates TRPA1 and causes irritation. These findings support a channel-specific response in the tested cells while leaving questions about TRPA1 distribution in skin.

Tranexamic Acid and Hydroquinone for Melasma

A February 20, 2023 ResearchGate listing describes an objective to compare topical tranexamic acid with hydroquinone for managing patients presenting with melasma. The provided material does not report the study's results, so it does not establish which treatment performed better. A separate 2026 article presents azelaic acid as an evidence-based alternative to hydroquinone for melasma and post-inflammatory hyperpigmentation, but the supplied excerpt gives no head-to-head results against tranexamic acid.

To confirm these findings, experiments were conducted using HEK 293 cells expressing hTRPA1. Results showed that pretreatment with DTT almost totally abolished HQ-induced HTRPA1 activation. These findings suggest that selective TRPA1 antagonists may be useful to counteract HQ-induced skin irritation.

A Future Without the Burn?

These findings open the door for developing new strategies to minimize HQ-induced skin irritation. By targeting TRPA1, scientists may be able to create skin-lightening products that are just as effective but far gentler on the skin.

AI Search Multiple angles on this topic

Future Directions for TRPA1 and Hydroquinone

A May 1, 2023 source describes TRPA1 as expressed by primary afferent nerve fibres, where it functions as a low-threshold sensor for structurally diverse electrophilic irritants. This provides context for research into how irritant chemicals may engage the channel. A 2026 hydroquinone trends page says it covers market growth, regulatory shifts, innovative formulations, efficacy, safety, and consumer demand, but the supplied excerpt gives no specific projections or findings.

Risks Beyond Irritation

A March 12, 2026 article describes hydroquinone as a skin-lightening agent associated with risks including irritation, paradoxical darkening, systemic absorption, and cancer concerns. The supplied excerpt does not quantify these risks or provide details about how often they occur. It frames hydroquinone's potential effects as extending beyond local irritation.

The research suggests that selective TRPA1 antagonists could be a valuable addition to HQ-based treatments, reducing the likelihood of irritation and improving patient compliance. This could mean a future where individuals can address hyperpigmentation without the discomfort that often accompanies it.

Further studies are needed to explore the potential of TRPA1 antagonists in mitigating HQ-induced irritation in humans. However, these initial findings offer a promising avenue for creating more tolerable and effective skin-lightening treatments, greatly improving the user experience.

TRPA1 responds at concentrations below those measured in treated skin

  • 5%In cells expressing human TRPA1, hydroquinone activated channel currents at concentrations as low as 10 μM; the estimated EC50 from calcium imaging was 17.1 μM. The paper compared this range with measured concentrations in skin tissue after application of 5% ointment.[1]

What the cell and mouse results add up to

Together, the cell experiments and mouse responses support TRPA1 as an important route by which hydroquinone can provoke irritation and pain. The mouse results show that blocking this channel greatly reduced those responses, but do not establish how well that would prevent irritation in people using topical products.[1] [2]

Hydroquinone also produced calcium responses in sensory neurons that were not fully explained by TRPA1, so the channel is not the only mechanism suggested by the experiments.[2]

What limits the hydroquinone-TRPA1 interpretation

  • The neuronal calcium responses were not entirely removed by accounting for TRPA1, pointing to additional mechanisms.[2]
  • Whether TRPA1 activation is necessary for hydroquinone’s skin-lightening effect remains unresolved in the paper.[1]

Hydroquinone irritation tested in human-TRPA1 cells and mice

PopulationHEK 293 cells expressing human TRPA1 and mice[2]
Main outcomeTRPA1 activation and HQ-induced pain or irritation responses[2]
Times cited8[2]

What remains unanswered about hydroquinone and TRPA1

  • How much do the cell and mouse findings explain irritation during topical hydroquinone use in people?[1] [2]
  • Does TRPA1 activation contribute to hydroquinone’s skin-lightening effect, or only to irritation-related responses?[1]

Terms used in the hydroquinone experiments

Hyperalgesia
An increased sensitivity to pain, measured in the mouse experiments as mechanical hyperalgesia.[1]
Agonist
A substance that activates a receptor; the paper identifies mustard oil as a TRPA1 agonist.[1]

Sources

  1. Involvement of Transient Receptor Potential Cation Channel Member A1 activation in the irritation and pain response elicited by skin-lightening reagent hydroquinone (Europe PMC, 2017)
  2. Involvement of Transient Receptor Potential Cation Channel Member A1 activation in the irritation and pain response elicited by skin-lightening reagent hydroquinone (Springer Science and Business Media LLC, 2017)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1038/s41598-017-07651-5, Alternate LINK

Title: Involvement Of Transient Receptor Potential Cation Channel Member A1 Activation In The Irritation And Pain Response Elicited By Skin-Lightening Reagent Hydroquinone

Subject: Multidisciplinary

Journal: Scientific Reports

Publisher: Springer Science and Business Media LLC

Authors: Yan Tai, Chuan Wang, Zhihua Wang, Yi Liang, Junying Du, Dongwei He, Xiaoyan Fan, Sven-Eric Jordt, Boyi Liu

Published: 2017-08-08

Everything You Need To Know

1

What is Hydroquinone and what is it used for?

Hydroquinone (HQ) is a common ingredient in skin-lightening products. It's used to treat hyperpigmentation disorders such as post-inflammatory hyperpigmentation, melasma, and solar lentigines. This means that it helps to reduce the appearance of dark spots or patches on the skin caused by various factors. While effective, HQ can cause skin irritation, limiting its use.

2

What is the role of the TRPA1 receptor in Hydroquinone-induced skin irritation?

The Transient Receptor Potential A1 (TRPA1) receptor plays a significant role. Research indicates that Hydroquinone (HQ) activates the TRPA1 receptor. This activation is a key mechanism in causing skin irritation. TRPA1 is found in sensory neurons and when activated, it triggers pain, itching, and inflammation. The study indicates the specific activation of TRPA1 by HQ, which helps explain why irritation occurs with HQ use.

3

How does Hydroquinone specifically interact with the TRPA1 receptor?

The research demonstrates that Hydroquinone (HQ) specifically activates TRPA1, while it does not activate other receptors such as TRPV1, TRPV4, or TRPM8. This specific interaction is important because it suggests that TRPA1 is a key target for the skin irritation caused by HQ. The activation of TRPA1 leads to the release of neuropeptides, causing neurogenic inflammation, pain, and itching.

4

Why is understanding the TRPA1 connection important for new skin-lightening treatments?

The implications of these findings are significant for the development of new skin-lightening treatments. By understanding that Hydroquinone (HQ) causes irritation by activating the TRPA1 receptor, scientists can work on ways to block or inhibit TRPA1. The goal is to create products that are as effective as Hydroquinone in lightening the skin but without the negative side effects of irritation. This could involve developing TRPA1 antagonists.

5

What is the significance of the redox sensitivity in the activation of TRPA1 by Hydroquinone?

The study suggests that the activation of TRPA1 by Hydroquinone (HQ) is redox-sensitive, meaning that it's related to the chemical interactions of HQ. This indicates that the effect of HQ on TRPA1 depends on its specific chemical properties. The results showed that pretreatment with DTT almost totally abolished HQ-induced hTRPA1 activation. Also, in mice, the injection of HQ caused acute pain and hyperalgesia, which were reduced by TRPA1 inhibitors.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.